Effect of 12 weeks training on muscular lipid handling in relation to type 2 diabetes mellitus

Not Applicable

Completed

• Conditions: Diabetes; Nutritional, Metabolic, Endocrine; Non-insulin-dependent diabetes mellitus

• Registration Number: ISRCTN43780395
• Lead Sponsor: The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Brief Summary

2011 results in https://pubmed.ncbi.nlm.nih.gov/21615922/ (added 23/10/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2008-07-18
• Study Start: 2009-08-28
• Last Update Posted: 2 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 11

Inclusion Criteria

All subjects:
1. Male sex
2. Aged 50 - 65 years
3. Body mass index (BMI) 27 - 35 kg/m^2
4. Stable dietary habits and physical activity levels

For diabetic patients only:
5. Must be on sulphonylurea or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months
6. Well-controlled diabetes: fasting plasma glucose concentration must be less than 10.0 mmol/l at the time of screening

For healthy controls only:
7. Normoglycaemic according to World Health Organization (WHO) criteria (oral glucose tolerance test [OGTT])

Exclusion Criteria

All subjects:
1. Female sex
2. Unstable body weight (weight gain or loss greater than 3 kg in the past three months)
3. Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
4. Active cardiovascular disease. This will be determined by performing an exercise electrocardiogram (ECG), by questionnaires and by screening on medication. Furthermore, all subjects will undergo a physical examination by a medical doctor.
5. Liver disease or liver dysfunction (alanine aminotransferase [ALAT] greater than 2.5 x increased)
6. Renal dysfunction (creatinine greater than 2 x increased)
7. Systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg
8. Haemoglobin less than 7.5 mmol/l (anaemia)
9. Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)
10. Use of anti-thrombotic medication
11. Claustrophobia and metal implants (with respect to magnetic resonance imaging [MRI])
12. Abuse of drugs and/or alcohol
13. Participation in another biomedical study within 1 month before the first screening visit

For diabetic subjects:
14. Severe diabetes which requires application of insulin or patients with diabetes-related complications

Study & Design

• Study Type: Interventional
• Study Design: Not specified